# MEMORANDUM — PRIVILEGED & CONFIDENTIAL / ATTORNEY WORK PRODUCT **To:** LumaBio General Counsel; VP Operations **From:** Outside Counsel **Re:** PrecisionFill vial-packaging line — liability, remedies, and disposition of the withheld $900,000 --- ## I. Executive summary LumaBio has a real but modest contract claim, a narrow and risky fraud claim, and a serious exposure on the withheld installment. The central legal fight is whether the operative performance standard is **300 vials/minute ("rated throughput")** or **285 vpm (the site-acceptance metric)**. Post-patch performance of 286–289 vpm means: - If **285** governs, PrecisionFill has substantially cured, LumaBio's recovery shrinks to incidental damages for the delay period, and withholding $900,000 is largely indefensible. - If **300** governs, PrecisionFill cannot cure without a feeder redesign it has never offered, the exclusive remedy fails, and LumaBio has a genuine diminution-in-value claim — but the consequential-damage exclusion still bars the lost customer order. The lost order (LumaBio's largest dollar item) is recoverable **only** through fraud, and LumaBio's own project-leader email badly damages reasonable reliance. Both sides hold damaging documents. **Recommendation: negotiate a commercial settlement built around a feeder/engineering upgrade, a defined sustained-performance protocol, and a partial price credit — while promptly curing LumaBio's own procedural defects (deduction notice, film compliance, HVAC records).** --- ## II. Breach of express warranty and other contractual obligations **A. The 300-vpm term is a written specification.** "Rated throughput: 300 vials per minute" is a factual description in the integrated writing, and PrecisionFill warranted for twelve months that the line "will conform to the written specifications." Under Rule 1, no formal warranty language is required; a description that becomes part of the basis of the bargain is an express warranty. LumaBio's strongest textual argument is that a *specification* cannot be surplusage: if 285 were the whole obligation, the 300 figure would have no operative content. **B. PrecisionFill's answer is contextual and strong.** "Rated" throughput reads naturally as nominal/design capacity — the nameplate — while the parties **expressly agreed** on the measure of conformity: a four-hour test averaging ≥285 vpm with ≤3% rejects, at 35–45% RH, on Schedule B–compliant film. Those conditions show the parties understood real-world output would depend on variables **LumaBio controlled** (humidity and film). The negotiated tolerance band (300 rated / 285 accepted) is a standard engineering allocation of that risk. **C. Likely outcome.** The term is genuinely ambiguous, which matters procedurally: ambiguity opens the door to extrinsic evidence (see Part III). On balance, a tribunal is more likely to hold that **285 vpm at the specified conditions is the contractual conformity threshold**, with 300 as a design rating — *but* that the twelve-month warranty is a continuing obligation, not a one-time gate, so the line must **sustain** ≥285 under specified conditions, not merely pass once. **D. Independent, non-throughput breaches (LumaBio's cleanest claims).** 1. **Defect in materials/workmanship:** the **feed-control software fault** is an admitted latent defect, breaching the express defect warranty independent of any throughput dispute. This claim does not depend on winning the 300 argument. 2. **Untimely cure:** six weeks to deliver a patch, following roughly three weeks of misdiagnosis (blamed on humidity), is a colorable failure to cure within a reasonable time (Rule 7). 3. **Sustained production validation:** the acceptance certificate conditioned acceptance on validation criteria never defined. PrecisionFill's own conduct — technicians working the performance problem from week one and issuing a patch — is course of performance confirming that both parties treated sustained performance as an open, unmet obligation (Rule 2). That defeats any waiver/final-acceptance defense. --- ## III. The pre-contract email: admissibility and fraud **A. As a contract term — excluded.** The VP's email ("300 all day … on your current film … we will take it back and make you whole") **contradicts** the writing in at least three ways: it displaces the 285/3% test standard, it drops the Schedule B film condition, and it substitutes a take-back/make-whole remedy for the exclusive repair remedy and the consequential-damage exclusion. Against a merger clause in a completely integrated agreement, Rule 2 bars its use to add or vary terms. **The project leader's internal email is close to fatal here:** it proves LumaBio recognized that the contract "only guarantees a 285 acceptance test," consciously decided not to add the 300 commitment, and signed anyway. That is deliberate omission, not integration failure. **B. As explanatory evidence — probably admissible, and this is the better use.** If "rated throughput: 300" is ambiguous, extrinsic evidence explaining it is not barred. The email is powerful evidence that the parties used "300" as a real performance expectation rather than a marketing figure. Frame the email as *interpretive*, not as an *additional term*. **C. As fraud — actionable in part, but reliance is the weak link.** - The take-back/make-whole sentence is a **promise of future performance**, actionable only if PrecisionFill had no present intent to perform (Rule 10). Thin. - "**This line will run 300 … on your current film**" is best characterized as a representation of **existing technical capability** of PrecisionFill's own architecture — squarely within Rule 10's actionable category, and information **peculiarly within the speaker's knowledge**. - **Scienter is excellent.** The internal chats — "this architecture probably tops out around 288 unless we redesign the feeder" and "**Do not put 288 in writing**" — supply knowledge or reckless disregard plus consciousness of concealment. The second message is the single most damaging document in the case and supports a willful-misconduct characterization, which pierces the liability caps and the consequential-damage exclusion. - **Corroboration:** even with **compliant** film the line "rarely exceeded 290." That neutralizes the film excuse as to the 300 figure and independently confirms the engineers' assessment. This is LumaBio's best causation point. - **But reliance is contested.** Under Rule 3 the merger and non-reliance clauses do not automatically defeat fraud based on an intentionally false factual statement within the speaker's knowledge — however, they are *relevant to reasonable reliance*, and LumaBio's own contemporaneous email shows its project leader **knew the contract did not include the 300 commitment and proceeded for scheduling reasons**. PrecisionFill will argue LumaBio assumed the risk with open eyes. - **Unclean hands / reciprocal concealment.** LumaBio held pre-contract QC data showing some film lots exceeded Schedule B limits (18% did in practice) and never disclosed it. The email's premise was "**your current film**." Expect a fraud or negligent-misrepresentation counterclaim, or at minimum a comparative-fault theme that neutralizes the jury appeal of PrecisionFill's chats. **Assessment:** the fraudulent-inducement claim is viable enough to plead and to create settlement leverage, but I would not bet the lost customer order on it. Also anticipate an economic-loss argument that the claim is coextensive with contract; fraudulent *inducement* usually survives, but it is a motion risk. --- ## IV. Acceptance, rejection, and revocation **A. Rejection is unavailable.** LumaBio signed a site-acceptance certificate after a full inspection opportunity and then ran the line commercially. That signifies acceptance under Rule 4. No effective rejection occurred. **B. The certificate's reservation preserves claims but creates no rejection right.** "Subject to punch-list items and sustained production validation" preserves warranty claims (which survive acceptance anyway) and defeats waiver, but because the sustained-production criteria were never defined, LumaBio cannot use it as an open-ended rejection option. **C. Revocation of acceptance will fail.** Rule 4 requires (i) substantial impairment of value and (ii) acceptance induced by difficulty of discovery or seller assurances, and Rule 4/5 require timely revocation before substantial change and without inconsistent use. - **Inducement element is satisfied** — the software defect was latent, and the technician's assurances blaming humidity are precisely the kind of assurance contemplated. - **Substantial impairment likely fails.** Post-patch, the line meets the agreed acceptance metric (286–289 vs. 285) and reaches 300 intermittently. A ~4% shortfall from the nameplate rating, on a functioning sterile line, is not substantial impairment of value. - **Timing and use are worse.** LumaBio used the line for **eight months** in ordinary production. Rule 5's limited-use exception protects use "necessary to avoid serious loss," not eight months of full commercial output. In a validated pharmaceutical environment, integration and process validation also constitute a substantial change. **Conclusion:** LumaBio is an accepting buyer confined to warranty damages on accepted goods plus the Rule 9 price-deduction mechanism. --- ## V. Notice Formal notice at **day 75** would ordinarily be late for an accepting buyer, but Rule 6 makes **actual seller knowledge** relevant, and PrecisionFill's technicians were on the performance problem **from the first week**, diagnosed the software fault themselves, and delivered a patch. There is no unfair surprise and no lost opportunity to cure — the classic notice rationale is satisfied. The day-25 "considering all contractual and legal remedies" email is additional early signaling. Notice should be held sufficient. The residual risk is a technical argument that service requests are not notice that the buyer *regards the seller as in breach*; that argument should lose on these facts but supports a modest litigation discount. --- ## VI. Failure of essential purpose — and why it matters less than it appears - **If 285 governs:** the repair remedy ultimately **worked**. Total cure time (~3 weeks of humidity-confounded diagnosis, then a 6-week patch) is defensible for a root-cause software fix in a complex sterile line, especially where LumaBio's incomplete HVAC caused the initial misdiagnosis. Likely **no** failure of essential purpose; LumaBio's recovery is limited to the value of lost use/incidental costs during the nonconformity window. - **If 300 governs:** PrecisionFill *cannot* cure without the feeder redesign its engineers identified and has never offered it. That is a seller who "cannot or will not provide an effective cure within a reasonable time" — the remedy **fails**, and LumaBio is released to general damages. - **Critically, the consequential-damage exclusion survives either way.** Rule 7 keeps such exclusions enforceable unless unconscionable or **expressly made dependent** on the exclusive remedy. Here the contract does the opposite — it expressly states the exclusion survives failure of the exclusive remedy. Between two sophisticated commercial parties, this is enforceable. **The only routes around it are fraud, gross negligence, or willful misconduct**, per the carve-out — which is why the "do not put 288 in writing" chat is the fulcrum of the entire case. --- ## VII. Damages | Category | Recoverable? | Analysis | |---|---|---| | **Diminution in value (300 promised vs. ~288 delivered)** | Yes, if 300 governs | Rule 8 direct damages. Measure by proportional capacity (~4% of $4.8M ≈ $190K) or, better, **cost to cure** = feeder redesign/retrofit cost. Get an independent engineering estimate now. | | **Nonconformity during 6-week patch window** | Likely yes | Direct/incidental loss of use attributable to an admitted defect. | | **238–260 vpm during the 3-week high-humidity period** | **No** | Caused by LumaBio's incomplete HVAC; outside the contractual test conditions; causation and mitigation both fail. | | **Overtime, temporary labor, expedited shipping** | **Contested — the key battleground** | LumaBio: incidental costs of dealing with nonconforming goods (Rule 8). PrecisionFill: disguised "lost production" expressly excluded. Expect partial recovery, apportioned to the software-defect period only, and reduced for out-of-spec film runs. | | **Lost customer order / lost profits / customer penalties** | **No, absent fraud** | Expressly excluded, and the exclusion survives failure of the exclusive remedy. Foreseeability (PrecisionFill's pre-contract knowledge) is irrelevant against an express exclusion. Recoverable only under the fraud/willful-misconduct carve-out, and then subject to reasonable-certainty proof. | | **Aggregate cap** | Purchase price ($4.8M) | Not a practical constraint except in a fraud scenario. | **Realistic recovery range on contract theories alone: roughly $250K–$700K**, driven mainly by cost-to-cure and apportioned incidental costs. A successful fraud claim could multiply that, but at materially less than 50% probability given the reliance problem. --- ## VIII. The withheld $900,000 Rule 9 permits deduction from the unpaid price **after notifying the seller of the intention to do so**. Two defects require immediate attention: 1. **Notice of intent to deduct.** The record shows a breach notice, not a clear deduction notice. Send a **formal deduction notice today** identifying the nonconformities, the theory of measurement, and a computed amount. 2. **Amount.** A deduction must approximate recoverable damages. $900,000 very likely exceeds LumaBio's provable direct plus incidental damages. Over-withholding is itself a breach exposing LumaBio to the shortfall, contract interest, and possibly fees, and it weakens the equitable optics of every other claim. **Recommended immediate step:** re-characterize the withholding — pay or escrow the portion above a defensible, engineer-supported damages estimate (e.g., retain $300K–$400K, tender or escrow the balance), with a written reservation of rights. This preserves leverage while removing PrecisionFill's cleanest counterclaim. --- ## IX. Spoliation of the telemetry - **Duty triggered:** LumaBio's day-25 email stating it was "considering all contractual and legal remedies," combined with PrecisionFill's technicians' first-hand knowledge of an escalating performance dispute, makes litigation reasonably anticipable before day 30 (Rule 11). - **Breach:** PrecisionFill failed to suspend a known 30-day auto-overwrite. That is at least negligent. - **Adverse inference: unlikely.** Rule 11 requires **intent to deprive**. Routine automated deletion, with summary reports preserved, points to negligence. Absent evidence that someone knowingly let the clock run to bury the data (worth targeted discovery: IT tickets, the technician's escalation emails, whether anyone considered a hold), no adverse-inference instruction. - **Curative measures are the realistic ask, and they are valuable.** The raw telemetry is precisely the data that would correlate output against humidity, film lot, and reject codes — i.e., PrecisionFill's own causation defense. Seek: (i) an order **precluding PrecisionFill from asserting what the raw telemetry would have shown**, or from relying on telemetry-derived humidity/film causation opinions; (ii) permission for LumaBio's expert to extrapolate adverse assumptions from the summary reports; (iii) cost-shifting for reconstruction; (iv) broad discovery of the engineers' chat platform (retention policy, deleted messages) — where any intent evidence would surface. - **Mirror risk:** LumaBio has its own duty. Its pre-contract film QC data, HVAC project records, film incoming-inspection records, and the project leader's email are all discoverable and all unhelpful. Issue/confirm a litigation hold immediately; a preservation failure by LumaBio on the QC data would be far more damaging than PrecisionFill's telemetry loss. --- ## X. PrecisionFill's strongest defenses 1. **Merger + non-reliance clauses**, weaponized by **LumaBio's own project-leader email** — the best single answer to both parol evidence and reasonable reliance. 2. **Film variance.** The acceptance test was expressly conditioned on Schedule B–compliant film; 18% of lots failed; LumaBio withheld pre-contract data showing it. This attacks the predicate of "on your current film," supports failure of a condition, and supports comparative fault. *Limitation:* compliant lots still rarely exceeded 290, so film cannot explain the gap to 300 — press this hard. 3. **Humidity.** Three weeks at 52–60% RH, outside the contractual band, from LumaBio's own incomplete HVAC project — defeats damages for that window and taints the causation record generally. 4. **Acceptance and 285 conformity.** Signed certificate; post-cure performance meets the agreed metric; "rated" means rated. 5. **Enforceability of the consequential exclusion**, expressly independent of remedy failure, between sophisticated parties — this alone likely eliminates the lost customer order absent fraud. 6. **Causation and mitigation.** Multi-causal shortfall; LumaBio delayed HVAC completion, failed to enforce film specs, waited 75 days to give formal notice, and ran the line for eight months, which both undercuts revocation and suggests the line's value was substantially intact. 7. **Counterclaim for the $900,000**, with interest and possibly fees. --- ## XI. Recommendation **Negotiate a commercial settlement, from a repaired procedural posture. Do not sue first.** Litigation is unattractive on both sides and roughly symmetric: PrecisionFill's "do not put 288 in writing" chat is a jury nightmare for it, but LumaBio's "procurement wants this signed today" email and its undisclosed film QC data are a jury nightmare for LumaBio. The contract's consequential-damage exclusion, which survives remedy failure, caps LumaBio's realistic contract recovery well below the amount withheld, and the only path to the lost order runs through a fraud claim with a serious reliance defect. **Sequence:** 1. **Now (7 days):** litigation hold; formal Rule 9 deduction notice with a computed amount; escrow the excess; independent engineering assessment of feeder-redesign scope and cost; commission the sustained-performance data analysis. 2. **Cure our own defenses (30–60 days):** implement incoming film inspection to Schedule B and document compliance; document HVAC stability at 35–45% RH. This produces a **clean test window** — post-patch performance on compliant film at compliant humidity is the single most valuable piece of evidence available and it costs little to create. If the line still tops out at ~288–290 under clean conditions, PrecisionFill's entire defense collapses and both the warranty and fraud claims strengthen dramatically. 3. **Demand additional engineering work as the primary relief**, not cash: a written **sustained-production validation protocol** (e.g., 30-day rolling average ≥295 vpm at 35–45% RH on compliant film, ≤3% rejects), the feeder redesign/retrofit at PrecisionFill's cost, on-site engineering support, and consumable/spare-parts coverage. This is what actually solves LumaBio's operational problem and is far cheaper for PrecisionFill than litigating its own chat logs. 4. **Settlement architecture:** release most of the $900,000 (roughly $550K–$700K) against (a) the feeder upgrade at PrecisionFill's cost, (b) a permanent credit of $200K–$350K, (c) extension of the express warranty to 24 months from validation with performance milestones and a stepped credit if the protocol is not met, (d) preservation and document-exchange stipulation, and (e) mutual releases carving out the new performance undertakings. 5. **Preserve, but do not lead with, the fraud claim.** Its function is leverage on the consequential-damage exclusion. Plead it only if negotiations fail and only after the clean-window test data is in hand — and be prepared for a reciprocal concealment claim over the film QC data. **Bottom line:** paying the full $900,000 concedes a legitimate defect and cure-delay claim; litigating for the lost customer order pursues a legally excluded damage item through a compromised fraud theory. The value-maximizing path is a negotiated fix — engineering performance plus a partial credit — executed from a position where LumaBio has eliminated the humidity and film defenses.